FREE ON-DEMAND WEBINAR
August 21, 2025
Raising Capital, Maximizing Exit: The Strategic Role of QMS in MedTech Growth
A strong Quality Management System isn’t just a regulatory requirement for early-stage MedTech companies—it’s a strategic advantage that accelerates growth, reduces risk, and strengthens your position for a successful exit.
In this on-demand session, you’ll hear from a MedTronic strategic acquirer, an investor from MedTech Syndicates, and the founder of SweetBio on why a clean, compliant, and well-structured QMS from day one directly shapes long-term success and acquisition outcomes.
The panel connects these perspectives across the full MedTech journey, from the pre-commercial stage, where an early QMS builds product confidence and investor trust, through post-commercial growth, where it becomes a driver of scalable operations and predictable revenue.
The conversation also offers an unfiltered look at acquisition readiness, breaking down how documentation quality shapes due diligence outcomes, impacts deal value, and ultimately influences whether a strategic acquirer decides to move forward.
What You’ll Learn:
- QMS as a Strategic Foundation: A tightly built QMS isn’t a bottleneck—it’s a non-negotiable element that removes friction for investors, partners, and future acquirers.
- Avoiding the Hidden “Landmines”: Delaying your QMS introduces risks that often stay invisible until it’s too late—leading to financial penalties, recalls, production stops, or lasting damage to your reputation.
- The Acquirer’s Lens: Strategic buyers like Medtronic are evaluating your ability to scale globally. Compliance gaps lower deal value or halt a deal altogether—they’re not interested in acquiring a “half-finished house.”
- Scalability Through Structure: A well-built QMS enables rapid growth by reducing chaos, supporting operational consistency, and preventing compliance-driven firefighting as orders and sales expand.
- Confident, High-Value Exits: Honesty, transparency, and early investment in a strong QMS serve as the “insurance policy” that positions your company for a clean, high-value acquisition.
Get free access to the full on-demand panel recording and slides now!
Access the On-Demand Webinar Resources!
QuickVault by Veeva is the leading device-to-market solution for MedTech companies. Built for full device lifecycle support, the platform unifies design, regulatory, quality, and post-commercial operations in one scalable environment—helping teams stay agile, compliant, and ready to grow.
From concept through commercialization and beyond, QuickVault by Veeva gives MedTech companies the visibility and control they need to deliver safe, effective products to patients and succeed at every stage.
Medtronic is a global medical technology company headquartered in Dublin, Ireland, that develops, manufactures, and sells medical devices and therapies. It operates through four segments: Cardiac and Vascular, Minimally Invasive Therapies, Restorative Therapies, and Diabetes. With approximately 95,000 employees, the company aims to alleviate pain, restore health, and extend life by creating innovative solutions for a wide range of conditions, from chronic diseases like diabetes to neurological disorders and surgical needs.
At MedTech Syndicates, we are committed to bridging the critical funding gap that exists during the early stages of MedTech innovation. We empower visionary clinicians to connect with early-stage MedTech companies, driving the development of cutting-edge medical devices, in vitro diagnostics, and digital health solutions.
Our platform is designed to facilitate collaboration between healthcare professionals and entrepreneurs, ensuring that innovative products reach the milestones needed to attract institutional investment.
By harnessing the collective expertise and passion of clinicians worldwide, we aim to accelerate the growth of MedTech innovations that have the potential to transform patient care and improve lives across the globe.
SweetBio is a medical device company bioengineering honey into wound care products. It is led by sibling duo Kayla Rodriguez Graff, Chief Executive Officer, and Dr. Isaac Rodriguez, Chief Science Officer. SweetBio is a 2015 graduate of the ZeroTo510 medical device accelerator, and is currently headquartered at the University of Memphis CommuniTech Research Park. They are committed to making their products accessible to all patients, and are voices in the movement to make startup economies more diverse and inclusive.